Jason P Rhodes sold $11M of DYN
director at Dyne Therapeutics, Inc.. 504,695 shares at an average of $21.23, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +15RoleDirector
- +25Trade size$10.7M at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001577014-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -162,954 | $21.28 | $3.5M | 4,579,456 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -81,903 | $21.28 | $1.7M | 1,396,475 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -64,411 | $21.28 | $1.4M | 1,016,633 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -102,969 | $21.14 | $2.2M | 4,476,487 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -51,756 | $21.14 | $1.1M | 1,344,719 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -40,702 | $21.14 | $860k | 975,931 | Jun 30, 2026 |
Related signals
Other insiders at Dyne Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | DYNbuy Dyne Therapeutics, Inc. | Brian S Posner director | $40k 2,500 shares | +10% | |
| 30Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $107k 5,658 shares | -2% | |
| 20Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $116k 5,035 shares | -3% | |
| 15Weak | Dyne Therapeutics, Inc. | Johanna Friedl-Naderer Chief Commercial Officer | $25k 1,085 shares | -1% | |
| 44Moderate | Dyne Therapeutics, Inc. | Erick Lucera Chief Financial Officer | $48k 2,362 shares | -2% | |
| 35Weak | Dyne Therapeutics, Inc. | Jason P Rhodes director | $5.6M 267,760 shares | -5% | |
| 35Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $5.5M 263,962 shares | -6% | |
| 35Weak | Dyne Therapeutics, Inc. | Dirk Kersten director | $1.7M 84,355 shares | -2% | |
| 27Weak | Dyne Therapeutics, Inc. | John Cox CEO & President | $49k 2,683 shares | -1% | |
| 10Weak | Dyne Therapeutics, Inc. | Douglas Kerr Chief Medical Officer | $16k 887 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.